Actively Recruiting
Phase II Trial Comparing GvHD Prevention Methods After Unrelated Donor Stem Cell Transplantation Using Thymoglobulin or Post-Transplant Cyclophosphamide with Calcineurin Inhibitor or Sirolimus
Led by University of Birmingham · Updated on 2026-05-05
400
Participants Needed
17
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase II randomized clinical trial to compare different methods of preventing graft-versus-host disease GvHD following reduced intensity conditioning unrelated donor allogeneic stem cell transplantation allo-SCT. The trial focuses on patients with various blood cancers including acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, lymphomas, and myelofibrosis. The study aims to evaluate GvHD-free, relapse-free survival among patients receiving different GvHD prophylaxis regimens. Participants are assigned to one of three groups one receiving Thymoglobulin with cyclosporine and mycophenolate mofetil MMF, another receiving post-transplant cyclophosphamide PTCy plus cyclosporine and MMF, and the last receiving PTCy plus sirolimus and MMF. Treatments include specific dosing schedules and administration routes over several days relative to transplant. The Thymoglobulin group receives infusions before transplant, while the PTCy groups receive cyclophosphamide after transplant with accompanying immunosuppressants. Doses and tapering schedules vary by arm and patient weight. Participants will be followed for at least one year after transplantation, during which researchers will monitor survival without GvHD or relapse, incidence of acute and chronic GvHD, infection rates, donor cell engraftment, immune function, quality of life, and safety outcomes. Assessments include blood tests, biopsies, questionnaires, and monitoring for infections and complications. The trial also explores immune system recovery and biomarker predictions related to GvHD and transplant outcomes.
CONDITIONS
Brief Title
Methods of T Cell Depletion Trial (MoTD)
Research Team
M
MoTD Trial
A
Andrea Dr Hodgkinson
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here